OS Therapies Inc (OSTX): Total Liabilities
$11.86M
As of 2025-12-31
$20.74M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.86M | +151.0% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $4.73M | -80.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $24.81M | n/a | 2025-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| OS Therapies Inc (OSTX) | 2025-12-31 | $11.86M | +151.0% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $6.99M | +12.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $1.40M | +43.1% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| Kairos Pharma, Ltd. (KAPA) | 2024-12-31 | $992.0K | -67.4% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $2.74M | -52.6% |
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $2.38M | -52.9% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $1.43M | +109.7% |
Compare OSTX, SER, CVSI, ADIL side by side · Screen every company in Pharmaceutical Preparations ↗